Company / Operating Income
Corcept Therapeutics Incorporated Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$44.8M
FY2025
5-year range
$44.8M / $137.0M
FY2021-FY2025
Trend
-67.3%
vs FY2024
Sector context
#46 of 204
Health Care
What the data says
Corcept Therapeutics Incorporated's operating income of $45M is higher than 77% of companies in the Health Care sector (FY2025). Operating Income has fluctuated over the past 10 years, ranging from -$28M in FY2016 to $137M in FY2024.
Based on SEC 10-K filings.
$45M in FY2025 with a 5-year CAGR of -12.9%. Top quartile in the Health Care sector.
Declined from $107M to $45M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -29.6%
- 5-Year CAGR
- -12.9%
- 10-Year CAGR
- -
Sector benchmark
-58.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -12.9%, indicating a declining trend.
- In FY2025, operating income decreased 67.3% year-over-year.
- Ranks #46 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.8M | -67.3% |
| FY2024 | $137.0M | +27.7% |
| FY2023 | $107.3M | -16.3% |
| FY2022 | $128.2M | +14.9% |
| FY2021 | $111.6M | +24.7% |
| FY2020 | $89.5M | +69.3% |
| FY2019 | $52.9M | +419.3% |
| FY2018 | $10.2M | -80.7% |
| FY2017 | $52.9M | +291.4% |
| FY2016 | -$27.6M | -702.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026